These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8389245)
21. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis]. Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638 [TBL] [Abstract][Full Text] [Related]
22. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789 [TBL] [Abstract][Full Text] [Related]
23. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Hashimoto T; Kobayashi Y; Ishikawa Y; Tsuchiya S; Okumura S; Nakagawa K; Tokuchi Y; Hayashi M; Nishida K; Hayashi S; Hayashi J; Tsuchiya E Cancer Res; 2000 Nov; 60(22):6472-8. PubMed ID: 11103815 [TBL] [Abstract][Full Text] [Related]
25. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816 [TBL] [Abstract][Full Text] [Related]
26. A novel molecular staging protocol for non-small cell lung cancer. Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061 [TBL] [Abstract][Full Text] [Related]
28. p53AIP1 expression can be a prognostic marker in non-small cell lung cancer. Yamashita SI; Masuda Y; Yoshida N; Matsuzaki H; Kurizaki T; Haga Y; Ikei S; Miyawaki M; Kawano Y; Chujyo M; Kawahara K Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):148-51. PubMed ID: 17851056 [TBL] [Abstract][Full Text] [Related]
29. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Gu J; Zhang L; Swisher SG; Liu J; Roth JA; Fang B Oncogene; 2004 Feb; 23(6):1300-7. PubMed ID: 14676844 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783 [TBL] [Abstract][Full Text] [Related]
31. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer. Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146 [TBL] [Abstract][Full Text] [Related]
32. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516 [TBL] [Abstract][Full Text] [Related]
33. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Sasatomi E; Finkelstein SD; Woods JD; Bakker A; Swalsky PA; Luketich JD; Fernando HC; Yousem SA Cancer Res; 2002 May; 62(9):2681-9. PubMed ID: 11980668 [TBL] [Abstract][Full Text] [Related]
34. Clinical significance of p53 in non-small-cell lung cancer. Komiya T; Hirashima T; Kawase I Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395 [TBL] [Abstract][Full Text] [Related]
35. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937 [TBL] [Abstract][Full Text] [Related]
36. [Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung]. Sánchez Céspedes M; López Cabrerizo MP; Moreno I; Ariza A; Monzó M; Rosell R Med Clin (Barc); 1997 May; 109(1):1-5. PubMed ID: 9303970 [TBL] [Abstract][Full Text] [Related]
37. p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. Karameris AM; Worthy E; Gorgoulis VG; Quezado M; Anastassiades OT J Pathol; 1995 Aug; 176(4):361-72. PubMed ID: 7562251 [TBL] [Abstract][Full Text] [Related]
38. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study. Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417 [TBL] [Abstract][Full Text] [Related]
40. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Murata M; Tagawa M; Kimura H; Kakisawa K; Shirasawa H; Fujisawa T Int J Oncol; 1998 Mar; 12(3):577-81. PubMed ID: 9472095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]